TuHURA Biosciences (NASDAQ:HURA) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of TuHURA Biosciences (NASDAQ:HURA) in a research report released on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $13.00 price objective on the stock.

Several other equities research analysts have also recently commented on the stock. Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price for the company. RODMAN&RENSHAW raised TuHURA Biosciences to a “strong-buy” rating in a research report on Thursday, December 19th. Finally, Maxim Group began coverage on TuHURA Biosciences in a research report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 target price for the company.

TuHURA Biosciences Stock Down 10.4 %

Shares of TuHURA Biosciences stock opened at $2.16 on Monday. The company’s 50 day simple moving average is $4.21. TuHURA Biosciences has a 52 week low of $2.16 and a 52 week high of $14.60.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Apollon Wealth Management LLC purchased a new stake in TuHURA Biosciences in the fourth quarter worth about $253,000. Suncoast Equity Management purchased a new stake in shares of TuHURA Biosciences in the 4th quarter worth approximately $421,000. Charles Schwab Investment Management Inc. bought a new position in TuHURA Biosciences during the 4th quarter valued at approximately $61,000. Accent Capital Management LLC purchased a new position in TuHURA Biosciences during the fourth quarter valued at $29,000. Finally, Geode Capital Management LLC bought a new stake in TuHURA Biosciences in the fourth quarter worth $1,084,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.